The renowned and contentious diabetes cure researcher Dr. Denise Faustman has just published exciting new research results showing evidence that "insulin production may persist for decades after the onset of type 1 diabetes" and "beta cell functioning also appears to be preserved in some patients years subsequently apparent going of pancreatic function." Her analyze results appears in the March issue of the journal Diabetes Care.

"The traditional conception is that in type 1 diabetes, the pancreas is dead within two years. What this information like a sho shows is that it's non an acute disease where the pancreas dies in that short interval. Rather, in the majority of mass, it's a piecemeal, slow decline," explained Dr. Faustman, when I spoke to her on the phone hold up week.

"This opens the motion of what is the window for mass with lengthy-phase diabetes to still stimulate a prospect of existence rescued. The time course of the disease is altered by this information!"

Dr. Faustman is nothing if not enthusiastic. One could even identify her as effervescing — which may account in role for the loving following she's amassed for her contentious approach to cure research, using a essence titled BCG vaccine to down unsatisfactory the cells that attack the insulin-producing cells in type 1 diabetics.

This fashionable information was most a byproduct of that work, she explains. Traditional "intervention" search focuses on patients newly diagnosed with diabetes, usually within one year. But Faustman's group could non afford the millions of dollars that big Pharma invests in locating and recruiting new onsets.

"Everybody's jockeying to try to bring fort these kids, but we can't contend at that level for a cheap generic dose (BCG), and also, we already had mouse data showing that BCG actually worked semipermanent," she says.

So her group recruited adult patients with long-term type 1 diabetes plane though they believed they were transaction with stillborn pancreases, she explains. When samples from these patients were dispatched turned to Sweden for an ultra-medium C-peptide test, one stunning result that came back was pancreas activity. "The norm in our group was 15 years out from diagnosis, and they all had some substance pancreas function. Actually, it's functioning at low activity but it's alive!" Faustman giggles.

What this means practically is that going forward, more PWDs should glucinium qualifying for clinical trials — as flat U.S. long-timers are today candidates for beta cell re-formation studies.

"It's kind of like renewed hope for patients. They're saying, 'you skilled my pancreas ISN't dead?' It's a new concept for people with typewrite 1 diabetes that their pancreas lives happening for a long time. This gives us a bigger windowpane of treatment than we had thought we had for a tenacious clock time," Faustman says.

Giving Reference, Determination Corroboration

Faustman is quick to point taboo that she's following in the footsteps of a certain Dr. Alan Foulis, a pathologist in the UK who for many years kept reportage that he saw islet cells in the cadavers of patients with type 1 diabetes. In the research world, "everybody poo-pooed it, because they…did the standardised C-peptide screen happening living patients and didn't see any function." Faustman says her new data is "the first functional data showing that the pancreas is on the job for a hourlong, aware time qualification insulin."

A certain Dr. Bart Roep supported in Leiden, Netherlands, mightiness disagree there. He appears to have scarce published a study that discovers exactly the said thing. "His discovery negates earlier enquiry which concluded that (insulin-producing) cells are completely abstracted in type 1 diabetes patients," according to an Expatica.com article with the unfortunate headline "European country Professor: Eccentric 1 Diabetes Can Be Cured." That sensational headline has the ill effectuate of making Dr. Reop sound like an unrealistic idealist, instead of a serious researcher whose findings indicate, in his ain language, that "i f these cells can be reactivated the patient could be cured, even as long as 10 years after the original diagnosing was made."

The work of Drs. Foulis and Roep is good news for Dr. Faustman, in the sense that her findings are supported aside the work of other researchers. The way I understand information technology, a want of documentation by her research peers is what makes Dr. Faustman's BCG work so controversial, and is besides the reason she hasn't received financial backin from established sources, like the JDRF.

Endless Honeymoon?

Naturally, I asked Dr. Faustman what this completely meant for the possibility of the "honeymoon phase" in type 1 diabetes. She says that previous thinking about the honeymoon lasting evenhanded 6 months operating theatre a year and then termination abruptly is in all likelihood false.

"The pancreas activity is gradually getting lower and lower — it's not a 6 months' decline, only at 10 or 20 years, the A1C's are acquiring worse. Everybody blames the patient, only it gets harder and harder to grapple," she says. Amun to that.

Faustman's BCG Trials Update

So what's happening with Dr. Faustman's BCG vaccine trials? They hope to restart Phase 2 fly studies within the year, she says. Of their $25 million goal, her group has raised $10 million in philanthropic donations hence far, "so we have got a ways to go — although this is cheap compared to other trials conducted by big Pharma," she says.

"We're now trying to sustain the vaccine in patients — to get eliminate the 'bad T-cells' so the pancreas has a high and higher chance of retrieval."

They'ray working with the Food and Drug Administration on guidelines for the work, which Faustman says is a new concept for the FDA, because the agency's modern guidelines focus on trials working to change the rank of decay of the pancreas. "Ours is the first data they've seen where the pancreas could represent turned back on, so the guidelines don't quite meet. What should the end points be? To what level act we have to turn the pancreas back connected (to be considered successful)? And for how long?"

They're also working on the Phase 2 tribulation design: pre-screening patients and shaping the population of subjects who should be included. "We've got people booked out for four geezerhood from all finished world who want to get pre-screened," she says. "Just about just want their name on the list, some lack to send us their clinical info, and some want to come visit and impart us blood samples."

Despite the onslaught, Faustman's still hopeful newborn patients to get in touch with her Hub of the Universe-based lab. If you're interested, visit World Wide Web.faustmanlab.org. No matter how long you've had type 1 diabetes, you'll be happy to know you no longer dusk in the "DEAD PANCREAS" file away.